Matricelf: How Much Runway Did the 2025 Financing Buy, and How Much Dilution Still Sits Ahead?

The main article argued that Matricelf’s 2025 financing bought time, not independence. This follow-up isolates only the capital-structure side of that claim: how much room the company actually bought, what accounting and equity cost has already been paid, and how much dilution still remains after the expiry and exercise wave at the start of 2026.

This matters because there are four different layers here, and they are easy to blur together: the cash that came in, the derivative liability that sat against part of it, the dilution that has already happened with almost no cash benefit, and the fact that the company itself is already telling investors that the Nasdaq route still requires fresh capital. A reader who looks only at year-end cash sees a cushion. A reader who connects all four layers sees a funded interim period, not a solved financing story.

That is the sharp read. October 2025 removed the immediate liquidity pressure, but it replaced it with a much more fragile capital structure. Since then, some warrants have disappeared without bringing in cash, others have already diluted holders through a cashless mechanism, and the remaining stack still depends on both the share price and the company’s ability to raise again.

What October 2025 Actually Bought

In gross cash terms, 2025 was clearly a different year from 2024. The company raised NIS 26.789 million gross in private financings during the year, with NIS 1.508 million of issuance costs. Inside that total, the October round alone amounted to NIS 24.434 million gross, with NIS 1.434 million of issuance costs. That is the number that moved Matricelf from a near-empty year-end 2024 cash position to something that looks like a real bridge into the next stage.

But even here, the structure matters. This was not one clean equity round at one clean price. The annual report records three rapid exercise waves of unlisted Series D warrants after October 27, 2025: 4,184,214 warrants exercised on October 28 for NIS 9.623 million, 5,115,547 exercised on November 4 for NIS 12.169 million, and 1,156,594 exercised on November 10 for NIS 2.638 million. In other words, the large cash inflow came through a warrant-driven equity mechanism, not through a simple, fully cleaned-up equity raise.

By year-end the company held NIS 17.424 million in cash and cash equivalents plus NIS 3.516 million of short-term deposits, together NIS 20.94 million of liquid resources. That is a major improvement versus year-end 2024. But for this article, the right frame is all-in cash flexibility, not only operating burn.

The all-in picture for 2025 is straightforward. Cash used in operating activities was NIS 14.795 million. Reported capital expenditure was NIS 597 thousand. Lease-related cash was another NIS 601 thousand, split between NIS 457 thousand of principal and NIS 144 thousand of interest. Together that is NIS 15.993 million of real cash use. If the increase in restricted deposits is added as well, from NIS 96 thousand to NIS 871 thousand, the number rises to NIS 16.768 million.

So the year-end liquidity base covered roughly 1.3 years at the 2025 all-in use rate, or roughly 1.25 years if the restricted-deposit build is included. And that is before two points the filings themselves make clear. First, 2025 did not yet carry a full human-trial cost base. Second, the company explicitly states that its current funding sources are not expected to support continued operations for the foreseeable future.

So yes, the financing bought time. It just did not buy enough time to erase the next raise.

The Derivative Liability Is the Real Cost of the Structured Tranche

The core of the story sits not in the cash balance but in the structured NIS 5.14 million tranche embedded inside the October financing. According to Note 11, a group of investors put in NIS 5.14 million and received a package that included 2 million shares, 2 million five-year warrants, and a right to invest another NIS 5.14 million within 180 days at 5% simple interest, in exchange for 2 million short-dated warrants and 4 million long-dated warrants. As of the date the annual statements were approved, that right had still not been exercised.

That is not just optionality. It became a financial liability. Section 3.16 explains that the current ratio fell to 1.30 from 5.29 mainly because of the derivative created by the 2025 private financings. The balance sheet at December 31, 2025 shows a current financial liability of NIS 14.054 million. Note 11 adds that the fair value of the derivative itself had already reached NIS 20.420 million by year-end.

The gap between the NIS 14.054 million balance-sheet liability and the NIS 20.420 million fair value disclosed in the note does not mean the risk is smaller. It reflects the accounting treatment of the day-one difference between transaction price and fair value. At initial recognition the derivative was valued at NIS 15.042 million, and the company deferred NIS 9.902 million of that gap. During 2025 it recognized NIS 3.536 million of loss from that deferred difference, on top of NIS 5.378 million of fair-value change.

The practical conclusion is that the derivative and the issuance costs allocated to it explain almost all of the 2025 financing expense spike. The income statement shows NIS 9.898 million of financing expense. Of that, NIS 8.914 million came from fair-value changes in financial liabilities, and another NIS 640 thousand was issuance cost attributed to the financial liability. That is NIS 9.554 million, about 96.5% of total financing expense for the year.

This is the point common shareholders need to hold onto. The October round did not only improve liquidity. It also created a heavy accounting and capital-structure layer that weakened near-term liquidity optics, loaded the finance line, and pushed part of the interim-funding cost directly onto equity holders.

Dilution Has Already Started, and the Remaining Stack Is Still Large

At year-end 2025 the company had 27.58 million issued and paid-up shares. But Note 15 shows how incomplete that number is as a read of the real capital structure. The company says diluted loss per share excluded 6.820 million share-based instruments, 13.167 million convertible instruments and warrants, and another 4.761 million listed Series 1 warrants. Together that is 24.748 million potential shares, almost 90% of the basic share count at year-end.

Of course, not every one of those instruments will turn into stock. Some of the stack already disappeared at the start of 2026. But even that happened in a way that was not particularly friendly to common holders. On January 30, 2026, 1,998,381 Series B warrants were exercised on a cashless basis and turned into 1,663,571 shares for only NIS 16,635, essentially the par value of the shares. At the same time, 818,041 unlisted Series D warrants and 536,922 additional unlisted warrants expired on January 31, 2026. On February 3, 2026, another 4,760,945 listed Series 1 warrants expired after the January 15 notice reminded investors that the exercise price was 866 agorot and the last trading day was January 28.

What does that mean in practice? Part of the overhang disappeared, but without bringing in meaningful cash. The late-January exercise diluted holders by 1.664 million new shares, while the expiry of the listed and unlisted warrants shut down theoretical funding paths that never materialized. That is not a clean deleveraging of the capital structure. It is a migration from open derivative-style overhang into a larger share base, without a real improvement in the company’s cash cushion.

The April 3, 2026 market snapshot strengthens that reading. Shares outstanding had already reached 29,244,761, up a little more than 6% from year-end 2025. At the same time, the share price stood at 339.7 agorot. That is already below the 385 agorot exercise price attached to the long-dated warrants in the structured tranche. The inference is straightforward: at the current market price, the remaining warrant layer does not look like an easy near-term cash source. It looks more like future negotiating leverage, or a capital-structure layer that may need another redesign.

How Much Time Is Left Before the Next Raise

The company itself gave the clearest answer in January 2026. In its January 27 update, it said it continues to advance the Nasdaq listing examination, has engaged legal counsel for that process, aims to complete the listing by the end of the first quarter of 2027, and estimates that it will need an additional $5 million to $10 million of capital for that purpose.

That is the critical point. Even if the derivative is ignored for a moment, and even if all year-end liquidity is treated as fully available for the clinical plan, the company is already telling shareholders that the next strategic step it wants still requires fresh money. Since the listed warrants expired without providing funding, and the late-January cashless exercise brought in almost no cash, that burden goes straight back to the capital markets or to a new financing structure.

The simplest way to say it is this: October 2025 bought Matricelf time to get closer to its clinical milestones. It did not buy the company freedom from another financing round. If anything, it made the pricing of that next round more sensitive, because investors now see the structured tranche, the dilution that has already arrived, and the fact that one full warrant layer already evaporated without funding the business.

Conclusion

The 2025 financing bought Matricelf an interim period, not a finish line. What supports the thesis is obvious: the company moved from an almost empty cash position to a balance that can fund another stage of progress. What still blocks a cleaner read is that this happened through a structure that created a heavy derivative liability, left behind a large dilution stack, and still ends with an explicit need to raise again before the next strategic step.

What changed versus the first read of the financing is not the idea that time was bought. It is the quality of the time that was bought. This is no longer just a financing bridge toward first-in-human preparation. It is a bridge with a double cost: outsized financing expense in the present, and continued equity uncertainty on the way to the next round.

Current thesis: October 2025 postponed Matricelf’s funding crunch, but it did not solve it. It bought roughly a year of room on a 2025 cash-use basis, while building a capital structure that can still weigh on common shareholders through both dilution and the need to return to the market before full clinical proof.